Facile synthesis of pH-responsive doxorubicin-loaded layered double hydroxide for efficient cancer therapy. Issue 36 (28th August 2018)

• Record Type: Journal Article
• Authors: Hakeem, Abdul; Zhan, Guiting; Xu, Qingbo; Yong, Tuying; Yang, Xiangliang; Gan, Lu
• Is Part Of: Journal of materials chemistry. Volume 6:Issue 36(2018)
• Page Start: 5768
• Page End: 5774
• Publication Date: 2018-08-28
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c8tb01572d
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : A method to load doxorubicin with positive charge into layered double hydroxide has been developed to improve its anticancer efficacy. Abstract : Layered double hydroxides (LDHs) have attracted particular attention as drug delivery carriers due to their variable chemical composition, excellent biocompatibility, high anion exchange capacity and controlled drug release. However, their anion exchange capability only meets the requirement for encapsulating drugs with negative charge in aqueous media. Encapsulation of drugs with positive charge into LDHs still remains a big challenge. Herein, we report a facile strategy to obtain highly dispersible doxorubicin-loaded MgAl-LDH nanohybrids (DOX@MgAl-LDH). DOX@MgAl-LDH is stable under physiological conditions and releases DOX in response to an acidic tumor microenvironment. Intracellular tracking of DOX@MgAl-LDH confirms that after internalization into cancer cells via macropinocytosis, clathrin- and lipid raft/caveolae-mediated endocytosis, DOX@MgAl-LDH is transported to lysosomes and then releases DOX to the nucleus. Furthermore, DOX@MgAl-LDH exhibits good tumor targeting, enhanced cellular uptake and cytotoxicity against cancer cells compared with free DOX. In vivo anticancer experiments reveal that DOX@MgAl-LDH significantly inhibits tumor growth with decreased DOX-induced cardiotoxicity compared with free DOX. This study may provide a new approach for highly efficient DOX delivery in cancer therapy.